COMPANY

Angiex, Inc.

HQ: Cambridge, MA source · angiex.com ↗ · New England

Angiex is developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality. From company website Source · Oct 12, 2026

Keywords: adc Breast Cancer Prostate Cancer Colorectal Cancer Pancreatic Cancer Liver Cancer Angiosarcoma AGX101

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Undisclosed round · $31M · announced Nov 14, 2025 Company release ↗
Source quote
- Nov 14, 2025 · Company release ↗
  “Angiex Completes Financings Totaling $31M to Support the Phase 1 Clinical Development of AGX101 in Patients with Advanced Solid Tumors CAMBRIDGE”

Raises announced in these releases: $31M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 14, 2025 Raise Undisclosed round · $31M source ↗
Jul 22, 2024 Trial start Phase 1: A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors source ↗

Upcoming milestones

Mar 6, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors · NCT06440005

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06440005	A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors	Phase 1	Recruiting	Jul 22, 2024	Mar 6, 2027 (estimated)